PHProstate Health
Digest
Testosterone / EVIDENCE GUIDE

Testosterone therapy and prostate safety: what the TRAVERSE trial changed

A large monitored trial found low, similar prostate-event rates in selected men, but its findings do not validate over-the-counter boosters.

Clinical Chemistry Analyzer
Clinical Chemistry Analyzer , Клинички биохемиски анализатор 2 · Делфина · CC BY-SA 4.0 · Source · License
THE KEY TAKEAWAY

TRAVERSE informs prescribed testosterone care in screened men; it does not prove that unregulated boosters are effective or risk-free.

A large trial answered a more specific safety question

Concern about testosterone and the prostate has influenced prescribing for years. The TRAVERSE program enrolled more than 5,000 middle-aged and older men with hypogonadism and cardiovascular disease or elevated cardiovascular risk. Participants were randomized to testosterone gel or placebo and followed under a protocol that included prostate screening and safety monitoring.

A prespecified prostate-safety analysis reported low rates of high-grade or any prostate cancer, acute urinary retention, invasive prostate procedures and new drug treatment for lower urinary tract symptoms. These outcomes did not differ significantly between groups during the trial. PSA increased somewhat more with testosterone, underscoring that laboratory monitoring still matters.

Blood collection tube
Blood Collection Tube 03 · AfroBrazilian · CC BY-SA 3.0 · Source · License

The reassuring result has boundaries

The findings apply to men who met trial criteria, had confirmed hypogonadism and received a standardized prescription product with clinical oversight. Men at higher prostate risk were excluded through baseline screening. Follow-up, while substantial for a testosterone trial, does not answer every question about use over decades or in populations not represented.

A result of no significant difference also should not be translated into zero risk. Event rates were low, which limits precision for uncommon outcomes. The trial supports a more evidence-based discussion of monitored therapy, not a guarantee for every individual.

FDA updated the policy context in 2026

In June 2026, FDA requested further updates to testosterone product labeling after reviewing TRAVERSE and other evidence. The agency said prescribing information should revise material related to prostate cancer and BPH while continuing monitoring recommendations for men with severe symptomatic disease. This followed 2025 class-wide cardiovascular labeling changes based on TRAVERSE and blood-pressure studies.

Regulatory updates do not turn testosterone into a general anti-aging supplement. FDA-approved testosterone products remain prescription medicines with specific indications, dosing and monitoring. A clinician's diagnosis of hypogonadism is different from fatigue, age or a marketing questionnaire that leads directly to a product sale.

Over-the-counter boosters are a separate evidence category

A botanical or nutrient sold as a testosterone booster is not the testosterone gel studied in TRAVERSE. Its ingredients, biological effect, quality and safety require their own evidence. A marketer cannot borrow prescription-drug trial results to imply that a proprietary booster has the same benefits or prostate-safety profile.

The reverse is also true: concern about an untested booster should not be used to describe the evidence for prescribed therapy. Keeping these categories separate helps readers evaluate the actual intervention. The relevant questions are what the product contains, whether it raises testosterone meaningfully, who was studied and what outcomes were measured.

Sphygmomanometer, automatic blood pressure monitor. Oscillometric measurements, millimeter of mercury (mmHg) unit.
Sphygmomanometer, automatic blood pressure monitor. Oscillometric measurements, millimeter of mercury (mmHg) unit · Albarubescens · CC BY-SA 4.0 · Source · License

Monitoring remains part of responsible care

Men considering prescribed testosterone should discuss symptoms, repeated laboratory testing, fertility goals, cardiovascular history, urinary symptoms and prostate evaluation with a qualified clinician. Those already using it should follow the monitoring plan rather than changing the dose in response to a supplement advertisement or a single lab value.

TRAVERSE changed the evidence by providing large randomized safety data in selected, screened men. It did not eliminate the need for individualized assessment, prove long-term safety for everyone or validate over-the-counter testosterone products. That distinction is the core of an informed prostate-safety conversation.

Do not infer a treatment need from a safety result

A safety trial can show that a monitored intervention did not produce a statistically significant excess of certain events in its enrolled population. It cannot show that everyone benefits from receiving the intervention. TRAVERSE participants had symptoms and repeatedly confirmed low testosterone under study criteria; the prostate analysis was not a test of testosterone for normal aging or athletic enhancement. Benefit decisions still require an appropriate diagnosis and a conversation about expected outcomes. The trial also cannot establish the composition of products sold online as boosters or prohormones. Those products may contain different ingredients and may never have been tested in comparable patients. Using TRAVERSE as a blanket endorsement of any testosterone-related product would confuse a defined prescription trial with an entire marketing category.

Sources & further reading

  1. Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial ↗
  2. Cardiovascular Safety of Testosterone-Replacement Therapy ↗
  3. FDA: Testosterone Information ↗
  4. HHS announces requested updates to testosterone therapy product labels ↗

This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.

More on Testosterone →